Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Short term Debt (2024 - 2025)

Kezar Life Sciences (KZR) has disclosed Short term Debt for 2 consecutive years, with $5.3 million as the latest value for Q3 2025.

  • Quarterly Short term Debt rose 34.91% to $5.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Sep 2025, up 34.91% year-over-year, with the annual reading at $5.2 million for FY2024, N/A changed from the prior year.
  • Short term Debt hit $5.3 million in Q3 2025 for Kezar Life Sciences, roughly flat from $5.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $5.3 million in Q2 2025 to a low of $1.3 million in Q1 2024.